Literature DB >> 34538573

A comprehensive framework for navigating patient care in systemic sclerosis: A global response to the need for improving the practice of diagnostic and preventive strategies in SSc.

Lesley Ann Saketkoo1, Tracy Frech2, Cecília Varjú3, Robyn Domsic4, Jessica Farrell5, Jessica K Gordon6, Carina Mihai7, Nora Sandorfi8, Lee Shapiro9, Janet Poole10, Elizabeth R Volkmann11, Monika Lammi12, Kendra McAnally13, Helene Alexanderson14, Henrik Pettersson14, Faye Hant15, Masataka Kuwana16, Ami A Shah17, Vanessa Smith18, Vivien Hsu19, Otylia Kowal-Bielecka20, Shervin Assassi21, Maurizio Cutolo22, Cristiane Kayser23, Victoria K Shanmugam24, Madelon C Vonk25, Kim Fligelstone26, Nancy Baldwin27, Kerri Connolly28, Anneliese Ronnow29, Beata Toth29, Maureen Suave30, Sue Farrington31, Elana J Bernstein32, Leslie J Crofford2, László Czirják3, Kelly Jensen33, Monique Hinchclif34, Marie Hudson35, Matthew R Lammi36, Jennifer Mansour37, Nadia D Morgan17, Fabian Mendoza38, Mandana Nikpour39, John Pauling40, Gabriela Riemekasten41, Anne-Marie Russell42, Mary Beth Scholand43, Elise Seigart44, Tatiana Sofia Rodriguez-Reyna45, Laura Hummers17, Ulrich Walker46, Virginia Steen47.   

Abstract

Systemic sclerosis (SSc), the most lethal of rheumatologic conditions, is the cause of death in >50% of SSc cases, led by pulmonary fibrosis followed by pulmonary hypertension and then scleroderma renal crisis (SRC). Multiple other preventable and treatable SSc-related vascular, cardiac, gastrointestinal, nutritional and musculoskeletal complications can lead to disability and death. Vascular injury with subsequent inflammation transforming to irreversible fibrosis and permanent damage characterizes SSc. Organ involvement is often present early in the disease course of SSc, but requires careful history-taking and vigilance in screening to detect. Inflammation is potentially reversible provided that treatment intensity quells inflammation and other immune mechanisms. In any SSc phenotype, opportunities for early treatment are prone to be under-utilized, especially in slowly progressive phenotypes that, in contrast to severe progressive ILD, indolently accrue irreversible organ damage resulting in later-stage life-limiting complications such as pulmonary hypertension, cardiac involvement, and malnutrition. A single SSc patient visit often requires much more physician and staff time, organization, vigilance, and direct management for multiple organ systems compared to other rheumatic or pulmonary diseases. Efficiency and efficacy of comprehensive SSc care enlists trending of symptoms and bio-data. Financial sustainability of SSc care benefits from understanding insurance reimbursement and health system allocation policies for complex patients. Sharing care between recognised SSc centers and local cardiology/pulmonary/rheumatology/gastroenterology colleagues may prevent complications and poor outcomes, while providing support to local specialists. As scleroderma specialists, we offer a practical framework with tools to facilitate an optimal, comprehensive and sustainable approach to SSc care. Improved health outcomes in SSc relies upon recogntion, management and, to the extent possible, prevention of SSc and treatment-related complications.
Copyright © 2021 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Disability; Interstitial lung disease; Pulmonary fibrosis; Pulmonary hypertension; Quality of life; Renal crisis; Scleroderma; Symptom burden; Systemic sclerosis

Mesh:

Year:  2021        PMID: 34538573      PMCID: PMC8670736          DOI: 10.1016/j.berh.2021.101707

Source DB:  PubMed          Journal:  Best Pract Res Clin Rheumatol        ISSN: 1521-6942            Impact factor:   4.991


  97 in total

1.  Experiences of physical activity and exercise in individuals with systemic sclerosis: A qualitative study.

Authors:  Henrik Pettersson; Annica Nordin; Elisabet Svenungsson; Helene Alexanderson; Carina Boström
Journal:  Musculoskeletal Care       Date:  2020-02-06

Review 2.  The patient experience of Raynaud's phenomenon in systemic sclerosis.

Authors:  John D Pauling; Lesley Ann Saketkoo; Marco Matucci-Cerinic; Francesca Ingegnoli; Dinesh Khanna
Journal:  Rheumatology (Oxford)       Date:  2019-01-01       Impact factor: 7.580

3.  Assessment of myocardial fibrosis and microvascular damage in systemic sclerosis by magnetic resonance imaging and coronary angiotomography.

Authors:  Tatiana S Rodríguez-Reyna; Martha Morelos-Guzman; Pablo Hernández-Reyes; Karla Montero-Duarte; Cynthia Martínez-Reyes; Carlos Reyes-Utrera; Jorge Vazquez-La Madrid; Jaime Morales-Blanhir; Carlos Núñez-Álvarez; Javier Cabiedes-Contreras
Journal:  Rheumatology (Oxford)       Date:  2014-09-18       Impact factor: 7.580

4.  Isolated diffusing capacity reduction in systemic sclerosis.

Authors:  V D Steen; G Graham; C Conte; G Owens; T A Medsger
Journal:  Arthritis Rheum       Date:  1992-07

Review 5.  Systemic Sclerosis: Gastrointestinal Disease and Its Management.

Authors:  Genevieve Gyger; Murray Baron
Journal:  Rheum Dis Clin North Am       Date:  2015-05-23       Impact factor: 2.670

6.  Unmet patient needs in systemic sclerosis.

Authors:  Tamara T Rubenzik; Chris T Derk
Journal:  J Clin Rheumatol       Date:  2009-04       Impact factor: 3.517

Review 7.  Race and association with disease manifestations and mortality in scleroderma: a 20-year experience at the Johns Hopkins Scleroderma Center and review of the literature.

Authors:  Allan C Gelber; Rebecca L Manno; Ami A Shah; Adrianne Woods; Elizabeth N Le; Francesco Boin; Laura K Hummers; Fredrick M Wigley
Journal:  Medicine (Baltimore)       Date:  2013-07       Impact factor: 1.889

Review 8.  Cardiac complications in systemic sclerosis: early diagnosis and treatment.

Authors:  Liu-Yan Nie; Xiao-Dong Wang; Ting Zhang; Jing Xue
Journal:  Chin Med J (Engl)       Date:  2019-12-05       Impact factor: 2.628

9.  Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial.

Authors:  Donald P Tashkin; Michael D Roth; Philip J Clements; Daniel E Furst; Dinesh Khanna; Eric C Kleerup; Jonathan Goldin; Edgar Arriola; Elizabeth R Volkmann; Suzanne Kafaja; Richard Silver; Virginia Steen; Charlie Strange; Robert Wise; Fredrick Wigley; Maureen Mayes; David J Riley; Sabiha Hussain; Shervin Assassi; Vivien M Hsu; Bela Patel; Kristine Phillips; Fernando Martinez; Jeffrey Golden; M Kari Connolly; John Varga; Jane Dematte; Monique E Hinchcliff; Aryeh Fischer; Jeffrey Swigris; Richard Meehan; Arthur Theodore; Robert Simms; Suncica Volkov; Dean E Schraufnagel; Mary Beth Scholand; Tracy Frech; Jerry A Molitor; Kristin Highland; Charles A Read; Marvin J Fritzler; Grace Hyun J Kim; Chi-Hong Tseng; Robert M Elashoff
Journal:  Lancet Respir Med       Date:  2016-07-25       Impact factor: 30.700

10.  Clinical and serological features of systemic sclerosis in a multicenter African American cohort: Analysis of the genome research in African American scleroderma patients clinical database.

Authors:  Nadia D Morgan; Ami A Shah; Maureen D Mayes; Robyn T Domsic; Thomas A Medsger; Virginia D Steen; John Varga; Mary Carns; Paula S Ramos; Richard M Silver; Elena Schiopu; Dinesh Khanna; Vivien Hsu; Jessica K Gordon; Heather Gladue; Lesley A Saketkoo; Lindsey A Criswell; Chris T Derk; Marcin A Trojanowski; Victoria K Shanmugam; Lorinda Chung; Antonia Valenzuela; Reem Jan; Avram Goldberg; Elaine F Remmers; Daniel L Kastner; Fredrick M Wigley; Pravitt Gourh; Francesco Boin
Journal:  Medicine (Baltimore)       Date:  2017-12       Impact factor: 1.817

View more
  2 in total

1.  Severity and mortality of COVID-19 in patients with systemic sclerosis: a Brazilian multicenter study.

Authors:  Sandra Maximiano de Oliveira; Lucas Victória de Oliveira Martins; Ana Paula Lupino-Assad; Ana Cristina Medeiros-Ribeiro; Daniela Aparecida de Moraes; Ana Paula Toledo Del-Rio; Maria Carolina Oliveira; Percival Degrava Sampaio-Barros; Cristiane Kayser
Journal:  Semin Arthritis Rheum       Date:  2022-02-25       Impact factor: 5.431

2.  A cell-based assay for detection of anti-fibrillarin autoantibodies with performance equivalent to immunoprecipitation.

Authors:  Gerson Dierley Keppeke; Minoru Satoh; Cristiane Kayser; Pedro Matos; Tomoko Hasegawa; Shin Tanaka; Larissa Diogenes; Rogerio Quintiliano Amaral; Silvia Helena Rodrigues; Luis Eduardo Coelho Andrade
Journal:  Front Immunol       Date:  2022-09-26       Impact factor: 8.786

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.